PASG
Passage BIO, Inc.
$5.81
+3.75%
$18.6M
No data for this timeframe.
Vol
Market Cap$18.6M
Cap SizeNano Cap
Analyst ConsensusBuy (64%)
Inst. Holders12 funds
Inst. Value$2.9M
Inst. Activity1 buys / 1 sells
SEC Reports3
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001787297·Prev Close $5.60
Recent Activity
Jun 5, 2026
SEC
Passage Bio terminated its research collaboration with Gemma Biotherapeutics for Huntington's disease and epilepsy progr
8-K — Impact 6/10
May 19, 2026
Insider
Countouriotis Athena was granted 10,539 shares
Director
May 19, 2026
Insider
GOWEN MAXINE was granted 10,539 shares
Director
May 19, 2026
Insider
Kapadia Sandip was granted 10,539 shares
Director
May 11, 2026
earnings_calendar
PASG Q1 2026 Earnings Scheduled — 2026-05-11
Apr 20, 2026
SEC
Passage Bio disclosed updated interim data from its Phase 1/2 upliFT-D trial for PBFT02, showing reduced brain atrophy a
8-K — Impact 6/10
Apr 7, 2026
SEC
Passage Bio, Inc. filed a definitive proxy statement for its 2026 Annual Meeting, which includes the election of two Cla
DEFA14A — Impact 2/10
Inst.
MORGAN STANLEY — TRIM
2,650 shares ($20.8K)
Price Targets
$12.67
+118.0% upside
Strong Buy
Current $5.81
Low $7.00
Median $8.00
High $23.00
3 analysts
$7.00
$23.00
Analyst Ratings
3Strong Buy
4Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 21, 2026 | TD Cowen | DOWNGRADE | Buy → Hold |
| Apr 21, 2026 | Chardan Capital | DOWNGRADE | Buy → Neutral |
| Apr 21, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Apr 21, 2026 | Wedbush | DOWNGRADE | Outperform → Neutral |
| Mar 31, 2026 | Oppenheimer | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.97 ▼ -19.6% | $-3.47 — $-2.20 | -0% YoY | 3 |
| Next Q | $-3.01 ▼ -19.2% | $-3.75 — $-1.89 | -24% YoY | 3 |
| Current FY | $-10.85 ▼ -16.0% | $-14.08 — $-8.60 | 24% YoY | 3 |
| Next FY | $-10.39 ▼ -35.3% | $-11.55 — $-9.23 | 4% YoY | 2 |
Latest Reports
BEARISH
8-K
6/10
Passage Bio terminated its research collaboration with Gemma Biotherapeutics for Huntington's disease and epilepsy progr
Jun 5, 2026
MIXED
8-K
6/10
Passage Bio disclosed updated interim data from its Phase 1/2 upliFT-D trial for PBFT02, showing reduced brain atrophy a
Apr 20, 2026
MIXED
Press
6/10
Passage Bio reported updated Phase 1/2 data showing PBFT02 reduced brain atrophy and stabilized plasma NfL in early-stag
Apr 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| RENAISSANCE TECHNOLOGIES LLC | $1.0M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $894.6K | — |
| Erste Asset Management GmbH | $526.9K | TRIM |
| BlackRock, Inc. | $224.5K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 19, 2026 | Countouriotis Athena | A | $0.00 |
| May 19, 2026 | GOWEN MAXINE | A | $0.00 |
| May 19, 2026 | Kapadia Sandip | A | $0.00 |
| May 19, 2026 | Porter Derrell | A | $0.00 |
| May 19, 2026 | Kassberg Thomas | A | $0.00 |
12 institutional holders with $2.9M total value (382,900 shares) as of 2026-Q1. Top holders: ROYAL, RENAISSANCE, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 2 | $0.00 | 0.0% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 133,612 | $1.0M | 36.6% | — |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 113,964 | $894.6K | 31.2% | — |
| 4 | Erste Asset Management GmbH | 85,262 | $526.9K | 18.4% | TRIM -30.6% |
| 5 | BlackRock, Inc. | 28,595 | $224.5K | 7.8% | — |
| 6 | VANGUARD FIDUCIARY TRUST CO | 17,049 | $133.8K | 4.7% | — |
| 7 | MORGAN STANLEY | 2,650 | $20.8K | 0.7% | TRIM -38.0% |
| 8 | Rockefeller Capital Management L.P. | 800 | $6.3K | 0.2% | ADD +60.0% |
| 9 | Vanguard Global Advisers, LLC | 638 | $5.0K | 0.2% | — |
| 10 | BARCLAYS PLC | 212 | $1.7K | 0.1% | DOUBLED +211.4% |
| 11 | WELLS FARGO & COMPANY/MN | 115 | $903.00 | 0.0% | — |
| 12 | CWM, LLC | 1 | $8.00 | 0.0% | NEAR_EXIT -80.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 4,275 | 2,650 | -38.0% | $20.8K | 2026-Q1 |
| Rockefeller Capital Management L.P. | ADD | 500 | 800 | +60.0% | $6.3K | 2026-Q1 |
| Erste Asset Management GmbH | TRIM | 122,790 | 85,262 | -30.6% | $1.0M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 338 | 4,275 | +1164.8% | $50.4K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 5 | 1 | -80.0% | — | 2025-Q3 |
| BARCLAYS PLC | DOUBLED | 4,224 | 13,153 | +211.4% | $9.2K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 14,486 | 3 | -100.0% | $1.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 2 | 14,486 | +724200.0% | $5.1K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 812,442 | 6,829 | -99.2% | $2.4K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 13,442 | 812,442 | +5944.1% | $460.7K | 2024-Q4 |
| STATE STREET CORP | ADD | 123,873 | 156,773 | +26.6% | $88.9K | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 158,261 | 402,525 | +154.3% | $281.8K | 2024-Q3 |
8 unique insiders with 8 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | Countouriotis Athena | Director | AWARD | 10,539 | — | — |
| May 19, 2026 | GOWEN MAXINE | Director | AWARD | 10,539 | — | — |
| May 19, 2026 | Kapadia Sandip | Director | AWARD | 10,539 | — | — |
| May 19, 2026 | Porter Derrell | Director | AWARD | 10,539 | — | — |
| May 19, 2026 | Kassberg Thomas Richard | Director | AWARD | 10,539 | — | — |
| May 19, 2026 | Sondhi Dolan | Director | AWARD | 10,539 | — | — |
| Mar 16, 2026 | Chou William | PRESIDENT AND CEO | AWARD | 58,000 | — | — |
| Mar 16, 2026 | Borthwick Kathleen | CFO | AWARD | 15,610 | — | — |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 4.7/10.
BEARISH
8-K
6/10
Passage Bio terminated its research collaboration with Gemma Biotherapeutics for Huntington's diseas
Jun 5, 2026
MIXED
8-K
6/10
Passage Bio disclosed updated interim data from its Phase 1/2 upliFT-D trial for PBFT02, showing red
Apr 20, 2026
NEUTRAL
DEFA14A
2/10
Passage Bio, Inc. filed a definitive proxy statement for its 2026 Annual Meeting, which includes the
Apr 7, 2026
Current analyst consensus: Buy (64% buy). Based on 11 analysts: 3 strong buy, 4 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$12.67 mean target
+118.0% upside
Strong Buy (2.50)
$7.00 Low
$23.00 High
| Metric | Value |
|---|---|
| Current Price | $5.81 |
| Target Low | $7.00 |
| Target Mean | $12.67 |
| Target Median | $8.00 |
| Target High | $23.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (2.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.97 | $-3.47 | $-2.20 | -0.2% | -19.6% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-3.01 | $-3.75 | $-1.89 | -23.5% | -19.2% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-10.85 | $-14.08 | $-8.60 | 24.4% | -16.0% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-10.39 | $-11.55 | $-9.23 | 4.3% | -35.3% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.967 | |
| 7d ago | $-2.480 | -0.487 |
| 30d ago | $-2.480 | -0.487 |
| 60d ago | $-2.652 | -0.315 |
| 90d ago | $-2.506 | -0.461 |
5 analyst firms have rated this stock: 0 upgrades, 3 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 21, 2026 | TD Cowen | DOWNGRADE | Buy | Hold |
| Apr 21, 2026 | Chardan Capital | DOWNGRADE | Buy | Neutral |
| Apr 21, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Apr 21, 2026 | Wedbush | DOWNGRADE | Outperform | Neutral |
| Mar 31, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Mar 4, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| May 1, 2026 | 3 | 4 | 5 | 0 | 0 | 58% | |
| Apr 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 11, 2026
earnings_calendar
PASG Q1 2026 Earnings Scheduled — 2026-05-11
Apr 20, 2026
fda
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
<p align="center"><em>PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing b
Mar 3, 2026
earnings
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
<p align="center"><em>Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study</em></p>
Mar 2, 2026
earnings_calendar
PASG Q4 2025 Earnings After Market Close — 2026-03-02